Relugolix for leiomyoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Jan 2024: Trial started, NCT06671548
  2. 4 Nov 2024: Trial registered, NCT06671548

The trials

NCT06671548: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

State
Under way
Phase
Phase 3
People
120 planned
Started
15 Jan 2024
Primary completion
12 Nov 2026
Arms
Relugolix plus megestrol acetate/medroxyprogesterone acetate (the treatment group)
Results
None posted
  1. 15 Jan 2024: Trial started
  2. 4 Nov 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Myfembree component relugolix, Orgovyx.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.